GlaxoSmithKline

مادة اعلانية

Latest Update: 10 June 2025 15:27 Abu Dhabi Time.

Market Status: Closed

BIOC

GlaxoSmithKline

40.66

EGP

-0.520

-1.26%

Open

41.18

Prev Close

41.18

PX_VOLUME

90,147

MARKET CAP (M)

DAY RANGE

39.06 - 41.70

52 WEEKS

24.70 - 47.30

Stock Statistics

Yearly Change

45.68%

Listed Shares (Million)

83.51

Earnings Multiple

14.21

Average 30-day trading volume

76,973.94

Price-to-book ratio

1.63

Earnings Per Share

2.08

Previous Dividend Distribution

0.71

Dividend Yield

0.00%

Financial Summary

Quarterly
Annual

Income Statements

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Revenue		993.91	847.49	787.08	642.45	713.81	663.47	576.44
Gross Profit		302.22	271.80	175.96	330.14	326.35	459.45	170.45
Operating Income		97.92	129.25	81.65	132.86	76.32	291.41	105.17
Profit Margin		5.95	8.04	1.69	15.81	-1.26	2.07	4.71

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Revenue		2,990.82	2,240.22	1,817.67	1,014.99	1,992.83
Gross Profit		1,104.25	843.33	572.53	307.04	779.84
Operating Income		420.08	440.90	18.94	11.49	202.51
Profit Margin		5.82	2.70	-6.26	-6.74	1.41

Balance Sheet

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Assets		4,613.67	3,652.63	3,712.12	3,744.61	3,971.75	3,557.92	3,557.41
Total Liabilities		2,504.73	1,657.08	1,784.72	1,830.48	2,089.49	1,592.59	1,605.81
Total Equity		2,108.94	1,995.56	1,927.40	1,914.13	1,882.26	1,965.33	1,951.60

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Assets		3,652.63	3,557.92	3,185.07	2,424.75	2,117.34
Total Liabilities		1,657.08	1,592.59	1,456.63	1,066.79	904.25
Total Equity		1,995.56	1,965.33	1,728.43	1,357.96	1,213.10

Cash Flows Statements - Coming Soon

* In Million of Egypt Pound

Reminder: The financial information on this website is delayed information that are originates from certified data providers in the financial markets, who retain the rights and intellectual property of this data, absolving ADMN of any responsibility.